Advertisement

Clinical Experience with Influenza Virus Sialidase Inhibitors

  • Philippe Buchy
Chapter
Part of the Milestones in Drug Therapy book series (MDT)

Abstract

The clinical experience of influenza virus sialidase inhibitors has been relatively limited, although over the past 5 years a number of studies have been undertaken that demonstrate the efficacy and indeed the potential issues of these drugs. This chapter provides an overview of aspects of this clinical experience including the current clinical use of these drugs, role of laboratory, pharmacological aspects of these antiviral drugs, as well as treatment and chemoprophylaxis in different infection scenarios (e.g. seasonal epidemics versus pandemics).

Keywords

Avian Influenza H1N1 Virus Personal Protective Equipment Pandemic H1N1 Neuraminidase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We would like to thank Prof. Frederick G. Hayden for his very valuable comments and kind assistance.

References

  1. 1.
    World Health Organization (2003, posting date) Fact sheet 211 Influenza. Available at: http://www.who.int/mediacentre/factsheets/fs211/en/index.html. Accessed 22 Sep 2009
  2. 2.
    Thompson WW, Shay DK, Weintraub E (2003) Mortality associated with influenza an respiratory syncitial virus in the United States. JAMA 289:179–86PubMedCrossRefGoogle Scholar
  3. 3.
    Terebuth P, Uyeki T, Kukuda K (2003) Impact of influenza on young children and the shaping of United States influenza vaccine policy. Pediatr Infect Dis J 22:S231–235Google Scholar
  4. 4.
    World Health Organization. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. Available at: http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf. Accessed 5 Jan 2010
  5. 5.
    Centers for Disease Control and Prevention (2008) Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR 57:1–61Google Scholar
  6. 6.
    Health Sciences Authority. Product safety alert: new preclinical findings on oseltamivir. March, 2004. Available at: http://www.hsa.gov.sg/publish/hsaportal/en/health_products_regulation/safety_information/product_safety_alerts/safety_alerts_2004/oseltamivir.html. Accessed 31 Jan 2010
  7. 7.
    Okamoto S, Kamiya I, Kishida K, Shimakawa T, Fukui T, Morimoto T (2005) Experience with oseltamivir for infants younger than 1 year old in Japan. Pediatr Infect Dis J 24:575–576PubMedCrossRefGoogle Scholar
  8. 8.
    Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, Dutkowski R, Hoffmann G, Breidenbach A, Lindermann L et al (2008) Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 31:1097–1114PubMedGoogle Scholar
  9. 9.
    Fritsch BF. FDA update on the H1N1 flu vaccine and antiviral medication. Available at: http://www.fda.gov/downloads/ForHealthProfessionals/UCM185724.pdf. Accessed 1 Feb 2010
  10. 10.
    Centers for Disease Control and Prevention. Emergency use authorization of peramivir IV fact sheet for health care providers. Available at: http://www.cdc.gov/h1n1flu/eua/Final%20HCP%20Fact%20sheet%20Peramivir%20IV_CDC.pdf. Accessed 31 Jan 2010
  11. 11.
    World Health Organization (2009) Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009. Wkly Epidemiol Rec 84:453–468Google Scholar
  12. 12.
    Mai LQ, Wertheim HFL, Duong TN, van Doorn RH, Hien NT, Horby P, for the Vietnam H1N1 Investigation Team (2010) A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 362:86–87CrossRefGoogle Scholar
  13. 13.
    Hurt AC, Ernest J, Deng Y (2009) Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South-East Asia and South Africa. Antiviral Res 83:90–93PubMedCrossRefGoogle Scholar
  14. 14.
    Hurt AC, Holien JK, Parker M, Kelso A, Barr IG (2009) Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 83:10366–10373PubMedCrossRefGoogle Scholar
  15. 15.
    Hayden FG (2006) Antiviral resistance in influenza viruses: implications for management and pandemic response. N Engl J Med 354:785–788PubMedCrossRefGoogle Scholar
  16. 16.
    Whitley RJ, Hayden FG, Reisinger KS (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20:127–133PubMedCrossRefGoogle Scholar
  17. 17.
    Moscona A (2004) Oseltamivir-resistant influenza? Lancet 364:733–734PubMedCrossRefGoogle Scholar
  18. 18.
    Kiso M, Mitamura K, Sakai-Tagawa Y (2004) Resistant influenza A Viruses in children treated with oseltamivir: descriptive study. Lancet 364:759–765PubMedCrossRefGoogle Scholar
  19. 19.
    Bardsley-Elliot A, Noble S (1999) Oseltamivir. Drugs 58:851–62PubMedCrossRefGoogle Scholar
  20. 20.
    Roche Laboratories, Inc. (2005) Tamiflu (oseltamivir for phosphate) capsules and oral suspension [Package insert]. Roche LaboratoriesGoogle Scholar
  21. 21.
    He G, Massarella J, Ward P (1999) Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64–0802. Clin Pharmacokinet 37:471–484PubMedCrossRefGoogle Scholar
  22. 22.
    Glaxo Wellcome, Inc. (2001) Relenza (zanamivir for inhalation) [Package insert]. Research Triangle Park, NC: Glaxo WellcomeGoogle Scholar
  23. 23.
    Cass LM, Brown J, Pickford M (1999) Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet 36:21–31PubMedCrossRefGoogle Scholar
  24. 24.
    LaForce C, Man CY, Henderson FW (2007) Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subject: a 28-day, multicenter randomized, double-blind, placebo-controlled trial. Clin Ther 29:1579–1590PubMedCrossRefGoogle Scholar
  25. 25.
    Medeiros R, Rameix-Welti MA, Lorin V, Ribaud P, Manuguerra JC, Socie G, Scieux C, Naffakh N, van der Werf S (2007) Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antivir Ther 12:571–576PubMedGoogle Scholar
  26. 26.
    Gaur AH, Bagga B, Barman S, Hayden R, Lamptey A, Hoffman JM, Bhojwani D, Flynn PM, Tuomanen E, Webby R et al (2010) Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 362:88–89PubMedCrossRefGoogle Scholar
  27. 27.
    Hayden FG, Treanor JJ, Friz RS (1999) Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282:1240–1246PubMedCrossRefGoogle Scholar
  28. 28.
    Treanor JJ, Hayden FG, Vrooman PS (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltaminir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283:1016–1024PubMedCrossRefGoogle Scholar
  29. 29.
    Nicholson KG, Aoki FY, Osterhaus AD (2000) Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355:1845–1850PubMedCrossRefGoogle Scholar
  30. 30.
    Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A (2006) Antivirals for influenza in healthy adults: systematic review. Lancet 367:303–313PubMedCrossRefGoogle Scholar
  31. 31.
    Anonymous (2007) New concerns about oseltamivir [Editorial]. Lancet 369:1056Google Scholar
  32. 32.
    Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, Dutkowski R, Hoffmann G, Breidenbach A, Lindermann L et al (2008) Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 31:1097–1114PubMedGoogle Scholar
  33. 33.
    Centers for Disease Control and Prevention. Relenza EUA, Fact sheet for Health Care Providers. Auhorized by FDA on October 30, 2009. Available at: http://www.cdc.gov/h1n1flu/eua/pdf/relenza_hcp_103009_fda_authorized_10.30.09.pdf. Accessed 1 Feb 2010
  34. 34.
    U.S. Food and Drug Administration. Relenza (zanamivir) inhalation powder. Available at: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm186081.htm. Accessed 31 Jan 2010
  35. 35.
    Gravenstein S, Johnston SL, Loeschel E (2001) Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications. Drug Saf 24:1113–1125PubMedCrossRefGoogle Scholar
  36. 36.
    Freund B, Gravenstein S, Elliott M, Miller I (1999) Zanamivir: a review of clinical safety. Drug Saf 21:267–281PubMedCrossRefGoogle Scholar
  37. 37.
    Hayden FG, Osterhaus AD, Treanor JJ (1997) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group. N Eng J Med 337:874–880CrossRefGoogle Scholar
  38. 38.
    Makela MJ, Pauksens K, Rostila T (2000) Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 40:42–48PubMedCrossRefGoogle Scholar
  39. 39.
    Monto AS, Fleming DM, Henry D (1999) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 180:254–261PubMedCrossRefGoogle Scholar
  40. 40.
    Tanaka TNK, Murashima A (2009) Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ 181:55–58PubMedCrossRefGoogle Scholar
  41. 41.
    Anonymous (2007) Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003–2006 influenza season. Wkly Epidemiol Rec 17:147–150Google Scholar
  42. 42.
    Wattanagoon Y, Stepniewske K, Lindergardh N, Pukrittayakamee S, Silachamroon U (2009) Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother 53:945–952PubMedCrossRefGoogle Scholar
  43. 43.
    Daniel MJ, Barnett JM, Pearson BA (1999) The low potential for drug interactions with zanamivir. Clin Pharmacokinet 36:41–50PubMedCrossRefGoogle Scholar
  44. 44.
    Hayden FG (2001) Perspectives on antiviral use during pandemic influenza. Philos Trans R Soc Lond B Biol Sci 356:1877–1184PubMedCrossRefGoogle Scholar
  45. 45.
    Moscona A (2005) Neuraminidase inhibitors for influenza. N Engl J Med 353:1363–1373PubMedCrossRefGoogle Scholar
  46. 46.
    Jain S, Karimoto L, Bramley AM (2009) Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 361:1935–1943PubMedCrossRefGoogle Scholar
  47. 47.
    Louie JK, Acosta M, Jamieson DJ, Honein MA, for the California Pandemic (H1N1) Working Group (2010) Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med 362:27–35CrossRefGoogle Scholar
  48. 48.
    World Health Organization. Clinical management of human infection with pandemic (H1N1) 2009: revised guidance, November 2009. Available at: http://www.who.int/csr/resources/publications/swineflu/clinical_management_h1n1.pdf. Accessed 10 Jan 2010
  49. 49.
    Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009–2010 season. Available at: http://www.cdc.gov/h1n1flu/recommendations.htm#b. Accessed 01 Feb 2010
  50. 50.
    Hurt AC, Holien JK, Parker MW, Barr IG (2009) Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 68:2523–2531CrossRefGoogle Scholar
  51. 51.
    Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S (2009) CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, show long-acting anti-influenza virus activity. Antimicrob Agents Chemother 53:186–192PubMedCrossRefGoogle Scholar
  52. 52.
    Writing Committee of the Second World Health Organization Consultation (2008) Clinical aspects of human infection with avian influenza A (H5N1) virus. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358:261–273CrossRefGoogle Scholar
  53. 53.
    Rameix-Welti MA, Agou F, Buchy P, Mardy S, Aubin JT, Veron M, van der Werf S, Naffakh N (2006) Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob Agents Chemother 50:3809–3815PubMedCrossRefGoogle Scholar
  54. 54.
    Yen HL, Monto AS, Webster RG, Govorkova EA (2005) Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 (H5N1) influenza virus in mice. J Infect Dis 192:665–672PubMedCrossRefGoogle Scholar
  55. 55.
    Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG (2007) Efficacy of oseltamivir thaerapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 51:1414–1424PubMedCrossRefGoogle Scholar
  56. 56.
    McKimm-Breschkin J, Selleck P, Usman TB, Johnson M (2007) Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis 13:1354–1357PubMedGoogle Scholar
  57. 57.
    de Jong MD, Thanh TT, Khanh TH (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353:2667–2672PubMedCrossRefGoogle Scholar
  58. 58.
    Saad MD, Boynton BR, Earhart KC (2007) Detection of oseltamivir resistance mutation N294S in humans with influenza A H5N1. In: Program and abstracts of the Options for the Control of Influenza Conference, Toronto, June 17–23, 228. abstractGoogle Scholar
  59. 59.
    World Health Organization. WHO rapid advice guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. 2006. Available at: http://www.who.int/medicines/pubblications/WHO_PSM_PAR_2006.6.pdf. Accessed 20 Dec 2007
  60. 60.
    World Health Organization. Clinical management of human infection with avian influenza A (H5N1) virus. Available at http://www.who.int/csr/disease/avian_influenza/guidelines/clinicalmanagement07/pdf. Accessed 20 Dec 2007
  61. 61.
    Ilyushina NA, Hoffmann E, Solomon R, Webster RG, Govorkova EA (2007) Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 12:363–370PubMedGoogle Scholar
  62. 62.
    Stittelaar KJ, Tisdale M, van Amerongen G, van Lavieren RF, Pistoor F, Simon J, Osterhaus AD (2008) Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. Antiviral Res 80:225–228PubMedCrossRefGoogle Scholar
  63. 63.
    Yun NE, Linde NS, Zacks MA, Barr IG, Hurt AC, Smith JN, Dziuba N, Holbrook MR, Zhang L, Kilpatrick JM (2008) Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 374:198–209PubMedCrossRefGoogle Scholar
  64. 64.
    Boltz DA, Ilyushina NA, Arnold CS, Babu YS, Webster RG, Govorkova EA (2008) Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res 80:150–157PubMedCrossRefGoogle Scholar
  65. 65.
    Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG (2007) Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 73:228–231PubMedCrossRefGoogle Scholar
  66. 66.
    Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG (2003) Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 326:1235PubMedCrossRefGoogle Scholar
  67. 67.
    Monto AS, Fleming DM, Henry D (1999) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 180:254–261PubMedCrossRefGoogle Scholar
  68. 68.
    Murphy KR, Eivindson A, Pauksens K (2000) Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled, multicentre study. Clin Drug Investig 20:337–349CrossRefGoogle Scholar
  69. 69.
    Hedrick JA, Barzilai A, Behre U (2000) Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 19:410–417PubMedCrossRefGoogle Scholar
  70. 70.
    Aoki FY, Macleod MD, Paggiaro P (2003) Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 51:123–129PubMedCrossRefGoogle Scholar
  71. 71.
    Kawai N, Ikematsu H, Iwaki N (2005) Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002–2003 influenza season. Clin Infect Dis 40:1309–1316PubMedCrossRefGoogle Scholar
  72. 72.
    Burch JPM, Conti S for the CRD/CHE Technology Assessment group (Centre for Reviews and Dissemination/Centre for Health economics), University of York. Influenza – zanamivir, amantadine and oseltamivir (review): assessment report, 2008. Available at: http://www.nice.org.uk:Guidance/TA168. Accessed 5 Jan 2010
  73. 73.
    Whitley RJ, Hayden FG, Reisinger KS (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20:127–133 [Published correction appears in Pediatr Infect Dis J. 20:421]PubMedCrossRefGoogle Scholar
  74. 74.
    Hayden FG, Pavia AT (2006) Antiviral management of seasonal and pandemic influenza. J Infect Dis 1:S119–126CrossRefGoogle Scholar
  75. 75.
    Lalezari J, Campion K, Keene O, Silagy C (2001) Zanamivir for the treatment of influenza A and B infection in high risk patients. Arch Intern Med 161:212–217PubMedCrossRefGoogle Scholar
  76. 76.
    Piedra PA, Schulman KL, Blumentalks WA (2009) Effects of oseltamivir on influenza-related complications in children with chronic medical complications. Pediatrics 124:170–178PubMedCrossRefGoogle Scholar
  77. 77.
    McCullers JA, Bartmess KC (2003) Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 187:1000–1009PubMedCrossRefGoogle Scholar
  78. 78.
    Kaiser L, Wat C, Mills T (2003) Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 163:1667–1672PubMedCrossRefGoogle Scholar
  79. 79.
    Johnston SL, Ferrero F, Garcia ML, Dutkowski R (2005) Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J 24:225–232PubMedCrossRefGoogle Scholar
  80. 80.
    Hanshaoworakul W, Simmerman JM, Narueponjirakul U, Sanasuttipun W, Shinde V, Kaewachana S, Areechokechai D, Levy J, Ungchusak K (2009) Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS One 4:e6051PubMedCrossRefGoogle Scholar
  81. 81.
    McGeer A, Green KA, Plevneshi A (2007) Antiviral therapy and out comes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 45:1568–1575PubMedCrossRefGoogle Scholar
  82. 82.
    Lee N, Chan PK, Choi KW (2007) Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 12:501–508PubMedGoogle Scholar
  83. 83.
    Sugaya N, Mitamura K, Yamazaki M, Tamuira D, Ichikawa M, Kimura K, Kawakami C, Kiso M, Ito M, Hatakeyama S (2007) Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 44:197–202PubMedCrossRefGoogle Scholar
  84. 84.
    Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami C, Kawaoka Y, Mitamura K (2008) Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 47:339–345PubMedCrossRefGoogle Scholar
  85. 85.
    Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, McGeer AJ, Neuzil KM, Pavia AT, Tapper ML (2009) Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 48:1003–1032PubMedCrossRefGoogle Scholar
  86. 86.
    Monto AS, Pichichero ME, Blanckenberg SJ (2002) Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 186:1582–1588PubMedCrossRefGoogle Scholar
  87. 87.
    Hayden FG, Belshe R, Villanueva C (2004) Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 189:440–9PubMedCrossRefGoogle Scholar
  88. 88.
    Hayden FG, Gubareva LV, Monto AS (2000) Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 343:1282–1289PubMedCrossRefGoogle Scholar
  89. 89.
    Welliver R, Monto AS, Carewicz O (2001) Effectiveness of oseltamivir in preventing influenza in household contracts: a randomized controlled trial. JAMA 285:748–754PubMedCrossRefGoogle Scholar
  90. 90.
    Bowles SK, Lee W, Simor AE (2002) Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999–2000. J Am Geriatr Soc 50:608–616PubMedCrossRefGoogle Scholar
  91. 91.
    Schilling M, Povinelli L, Krause P (1998) Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 16:1771–1774PubMedCrossRefGoogle Scholar
  92. 92.
    Peters PH Jr, Gravenstein S, Norwood P (2001) Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 49:1025–1031PubMedCrossRefGoogle Scholar
  93. 93.
    Monto AS, Rotthoff J, Teich E (2004) Detection and control of influenza outbreaks in well-vaccinated nursing home population. Clin Infect Dis 39:459–464PubMedCrossRefGoogle Scholar
  94. 94.
    Vu D, Peck AJ, Nichols WG (2007) Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis 45:187–193PubMedCrossRefGoogle Scholar
  95. 95.
    Brokstad KA, Cox RJ, Olofsson J (1995) Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis 171:198–203PubMedCrossRefGoogle Scholar
  96. 96.
    Lawson F, Baker V, Au D (2000) Standing orders for influenza vaccination increased vaccination rates in inpatient settings compared with community reates. J Gerontol A Biol Sci Med Sci 55:M522–526PubMedCrossRefGoogle Scholar
  97. 97.
    Tappenden PJR, Cooper K (2009) Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): systematic review and economic evaluation. Health Technol Assess 13:1–268Google Scholar

Copyright information

© Springer Basel AG 2012

Authors and Affiliations

  1. 1.Institut Pasteur in Cambodia, Virology UnitPhnom PenhCambodia

Personalised recommendations